September 15, 2021

SOPHIA Phase III study of Margenza announces final OS data in HER2-positive breast cancer patients – MacroGenics

MacroGenics announced the final overall survival (OS) results of the SOPHIA Phase III study of Margenza (margetuximab-cmkb) in adult patients with metastatic HER2-positive breast cancer. The final OS analysis of the SOPHIA study was performed after 385 OS events occurred in the intent-to-treat (ITT) population. As per the study protocol, OS was defined as the number of days from randomization […]

admin Health 0 2 min read
September 12, 2021

Stem-like T cells could aid immunotherapy in cancer treatment

In a new study by Yale Cancer Center, researchers show stem-like T cells within certain lymph nodes could be natural cancer fighters. Targeting these T cells, which are a type of white blood cells, with immunotherapy drugs could increase the number of cancer patients that respond to treatment. The findings were reported online today in the journal Science Immunology. “Therapies that […]

admin Health 0 2 min read
September 5, 2021

Making CAR-T therapy most effective in leukaemia patients

Too many “exhausted” T cells left in the wake of aggressive chemotherapy regimens for patients with advanced chronic lymphocytic leukaemia (CLL) make it more challenging for chimeric antigen receptor (CAR) T cell therapy to do its job. Now, a new study from researchers at the University of Pennsylvania shows how to overcome this type of resistance and reinvigorate these T […]

admin Health 0 2 min read
August 16, 2021

Statins appear to improve survival in triple-negative breast cancer

Researchers report an association between statin therapy and improved survival rates among triple-negative breast cancer patients. The findings appeared on Aug. 3, 2021 in the journal Cancer. “We know that statins decrease breast cancer cell division and increase cell death,” said investigator Kevin Nead, M, assistant professor of epidemiology at the University of Texas M.D. Anderson Cancer Center in Houston, […]

admin Health 0 1 min read
August 9, 2021

FDA approves Keytruda to treat high-risk early-stage triple-negative breast cancer – Merck Inc.

Merck Inc. announced that the FDA has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment and then continued as a single agent as adjuvant treatment after surgery, based on the Phase III KEYNOTE-522 trial. TNBC is an aggressive type of breast cancer with an […]

admin Health 0 1 min read

Recent Posts

Meta

Categories

Archives

Recent Comments